Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

Original from: Quanterix 

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025.

“I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of Quanterix. “During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer’s Diagnostics business.  With most of the major integration milestones now behind us, our focus now turns to driving consistent profitable revenue growth and achieving cash flow breakeven performance in 2026.  My immediate focus is on spending time with the Quanterix team, customers, shareholders, and partners as I evaluate the Company’s strategy and future potential and ensure that we have the resources, support and capabilities to deliver on our operational priorities. I am extremely optimistic for what the future holds for Quanterix.”  

Fourth Quarter Financial Highlights

- Revenue of $43.9 million, an increase of 25% compared to $35.2 million in the prior year.

- GAAP gross margin of 45.7%, as compared to 63.0% in the prior year. Adjusted gross margin (non-GAAP) of 50.0% as compared to 57.7% in the prior year. 

- Adjusted EBITDA (non-GAAP) loss of $7.9 million, compared to a loss of $5.9 million in the prior year.

- The Company ended the fourth quarter with $121.6 million of cash, cash equivalents, marketable securities, and restricted cash, compared to its guidance of $120 million. Adjusted cash usage, after accounting for one-time deal and restructuring costs, was $3.0 million in the fourth quarter.  

Full Year 2025 Financial Highlights

- Revenue of $138.9 million, an increase of 1% compared to $137.4 million in the prior year.

- GAAP gross margin of 46.8%, as compared to 60.5% in the prior year. Adjusted gross margin (non-GAAP) of 47.3% as compared to 54.6% in the prior year.

- Adjusted EBITDA (non-GAAP) loss of $44.9 million, compared to a loss of $23.6 million in the prior year.    

- The Company ended the fourth quarter with $121.6 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for one-time deal and restructuring costs, was $30.9 million in 2025 compared to $32.2 million in the prior year.

Operational and Business Highlights

- In January 2026, Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its multi-analyte algorithmic blood test for Alzheimer’s disease.  This submission represents a significant milestone in the Company’s mission to provide superior, non-invasive, high-performance diagnostic tools to aid in the evaluation of patients with cognitive symptoms for possible Alzheimer’s disease. 

- The Centers for Medicare & Medicaid Services (“CMS”) established a reimbursement rate of $897 for Quanterix’s LucentAD Complete test, facilitating claims submissions under the Clinical Lab Fee Schedule. This milestone provides a nationally recognized reference price, an important step for coverage decisions with payers, and supports efforts to bring this multiplex diagnostic solution to patients across the country. 

- The Company announced that it has already implemented $74 million of cost savings related to its Akoya transaction.  With 94% of the integration milestones now complete, the Company expects to capture its remaining cost synergies by the end of the first quarter of 2026.  

- Launched 13 new assays in 2025, including two new Simoa tau assays, pTau 205 and pTau 212, and two new Phenocode Discovery panels, in Q4 2025 – Metabolism Spike In Panel and Mouse Neurology Panel.

2026 Business Outlook

Quanterix is issuing its initial guidance for 2026.  The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49% to 53%.  

Quanterix expects to achieve cash flow breakeven performance in the second half of 2026.  The Company expects to exit the year with approximately $100 million in cash and no debt. 

Source: Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025.